


Naldemedine tosylate

Cat. No.:	HY-19627A
CAS No.:	1345728-04-2
Molecular Formula:	C ₃₉ H ₄₂ N ₄ O ₉ S
Molecular Weight:	742.84
Target:	Opioid Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	-20°C, stored under nitrogen, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)



BIOLOGICAL ACTIVITY

Description	Naldemedine (S-297995) tosylate is an orally active μ -opioid receptor antagonist (PAMORA) ^[1] . Naldemedine tosylate shows potent binding affinities (K_i =0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC_{50} =25.57, 7.09, 16.1 nM, respectively) for recombinant human μ -, δ -, and κ - opioid receptors ^[2] . Naldemedine can be used in opioid-induced constipation (OIC) research ^[2] . Naldemedine tosylate is predicted to bind to 3CL ^{PRO} encoded by SARS-CoV2 genome ^[3] .
IC₅₀ & Target	μ Opioid Receptor/MOR
In Vivo	Naldemedine tosylate (oral gavage; 0.03-10 mg/kg; once) represses the opioid-induced inhibition of small intestinal transit in rats ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:	6-week-old Wistar and SD male rats ^[2]
Dosage:	0.03-10 mg/kg
Administration:	Oral gavage; 0.03-10 mg/kg; once
Result:	Repressed the subcutaneous inhibition of small intestinal transit in rats with an ED ₅₀ of 0.03 mg/kg

REFERENCES

- [1]. Hannah A. Blair. Naldemedine: A Review in Opioid-Induced Constipation. *Drugs*. 2019 Jul;79(11):1241-1247.
- [2]. Toshiyuki Kanemasa, et al. Pharmacologic effects of naldemedine, a peripherally acting μ -opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation. *Neurogastroenterol Motil*. 2019 May;31(5):e13563.
- [3]. Sugandh Kumar, et al. Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity. *Comput Struct Biotechnol J*. 2021;19:1998-2017.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA